v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s structure is aligned with how the chief operating decision maker (“CODM”) reviews the business, makes investing and resource allocation decisions and assesses operating performance. The Company’s CODM is its Chief Executive Officer. As of March 31, 2025, the Company has identified one reportable segment: GeneDx inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Other represents the revenues and costs associated with the Legacy Sema4 diagnostics business which was completely shut down in 2023.
The CODM evaluates segment performance based on revenue and adjusted gross profit.
Three months ended March 31,
20252024
GeneDxOtherTotalGeneDxOtherTotal
Revenue$87,115 $— $87,115 $61,461 $961 $62,422 
Adjusted cost of services27,396 — 27,396 24,099 — 24,099 
Adjusted gross profit (1)
59,719 — 59,719 37,362 961 38,323 
Reconciliations:
Depreciation and amortization1,075 816 
Stock-based compensation168 48 
Restructuring costs— 48 
Gross profit$58,476 $37,411 
(1)Adjusted cost of services and adjusted gross profit exclude depreciation and amortization expense, stock-based compensation expense and restructuring costs.
Management manages assets on a total company basis, not by reporting segment. The CODM does not regularly review any asset information by reporting segment and, accordingly, the Company does not report asset information by reporting segment.